{
  "completed": true,
  "status": "completed_original_source_reconciliation",
  "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings",
  "queries": [
    "https://consensus.app/search/laetrile-amygdalin-cancer-treatment/r2qpQ4-GS1mql46fgAIFzg/"
  ],
  "query_record_note": "Exact visible question/response retained privately in raw browser receipt.",
  "primary_comparison_count": 11,
  "primary_comparisons": [
    {
      "pmid": "7033783",
      "doi": "10.1056/NEJM198201283060403",
      "source_type": "primary study report",
      "study_group": "PMID7033783",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Consensus reports the178-patient nonrandomized regimen and explicitly limits original access to its abstract.",
      "result_comparison": "Our original abstract check agrees: practitioner-like metabolic programme, no substantive benefit and cyanide hazards. The175 evaluable/one temporary partial response detail is supplied by a later review in Consensus and by auxiliaryNCIcontext in our check; it is not directly verified in an original trial body. Do not call this an RCT or zero responses.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/7033783/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\examinations\\original-0-15-4000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "683212",
      "doi": "10.1056/NEJM197809072991013",
      "source_type": "primary study report",
      "study_group": "PMID683212",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Provider emphasizes negative clinical evidence but does not detail the original favorable case-record submission analysis.",
      "result_comparison": "The original1978 abstract retains six responses judged by a blinded oncology panel, while only presumed-success cases were solicited and incomplete records excluded. These observations justify interest without proving a treatment effect or becoming an independent controlled trial.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/683212/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\examinations\\original-64-65-6000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "7005480",
      "doi": "",
      "source_type": "primary study report",
      "study_group": "NCI_CLINICAL_PHARMACOLOGY_PROGRAMME",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Consensus correctly reports oral/IV differences and the raw-almond interaction from the original pharmacology abstract.",
      "result_comparison": "Original six-patient abstract confirms low observed toxicity withIVadministration, increased oral cyanide and transient symptoms in one almond-challenged patient. Small route-specific observations cannot prove safety of every IV dose or efficacy.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/7005480/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\examinations\\original-0-15-4000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "7273266",
      "doi": "10.1007/BF00253010",
      "source_type": "primary study report",
      "study_group": "NCI_CLINICAL_PHARMACOLOGY_PROGRAMME",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Provider discusses clinically attainable exposure and oral versusIV activation.",
      "result_comparison": "Original pharmacology distinguishes high, briefIVparent plasma levels from very low oral parent levels with cyanide increase. These are parent plasma measurements, not sustained tumour concentration. Culturemg/mL activity cannot be equated to the same human exposure.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/7273266/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\examinations\\original-0-15-4000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "37726740",
      "doi": "10.1186/s12906-023-04142-1",
      "source_type": "primary study report",
      "study_group": "PMID37726740",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Consensus acknowledges matched-normal positive studies but does not report the examined original cell-pair dose limits.",
      "result_comparison": "Original Results verifies HepG2 versusWI38 differentialIC50 and sorafenib synergy atmg/mL concentrations. Unmatched tissue types, cell proliferation and missing whole-organ exposure still limit a human therapeutic window; the positive comparator is retained.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/37726740/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\examinations\\original-45-65-3600.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\body-presentation-receipts\\37726740-s2-p0-15-25.json"
      ]
    },
    {
      "pmid": "39519581",
      "doi": "10.3390/nu16213750",
      "source_type": "primary study report",
      "study_group": "PMID39519581",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Provider's preclinical summary could be read as broad monodrug activity.",
      "result_comparison": "Original body distinguishes minimal growth effect from1 mg/mLalone from strong sulforaphane-combination effects, and reports no induced apoptosis in those assays. A low dose in that protocol is not verified patient exposure.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/39519581/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\examinations\\original-45-65-3600.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\body-presentation-receipts\\39519581-s2-p0-1-3.json"
      ]
    },
    {
      "pmid": "32636623",
      "doi": "10.2147/IJN.S242359",
      "source_type": "primary study report",
      "study_group": "PMID32636623",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Provider emphasizes nanocarriers as a technical advance rather than clinical validation.",
      "result_comparison": "Original magnetic-enzyme Results agree with a restricted delivery benefit and retain inactive targeting controls. AST, CK and LDHincrease despite no obvious organ histology injury. Neither the carrier norenzyme addition is historical free-drug therapy, and limited histology cannot be labeled complete safety.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/32636623/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\examinations\\original-45-65-3600.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\body-presentation-receipts\\32636623-s2-p7-21-28.json"
      ]
    },
    {
      "pmid": "36355478",
      "doi": "10.3390/ph15111306",
      "source_type": "primary study report",
      "study_group": "PMID36355478",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Consensus supplies a new niosomal-gel animal lead and a provider release graphic.",
      "result_comparison": "Original record and selected Methods/Results were examined: thirty rats in small DMBA groups, topical loaded gel versus blank gel/oral free compound, reduced local carcinoma volume and skin pathology. These results remain positive in their context, but do not measure a human regimen, systemic cyanide margin or complete normal-organ safety. Provider graphics are not republished.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/36355478/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\examinations\\original-65-67-6000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\body-presentation-receipts\\36355478-s1-p8-9-10.json",
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\body-presentation-receipts\\36355478-s2-p13-14-15-16-17-18-19-20-21.json"
      ]
    },
    {
      "pmid": "32097740",
      "doi": "10.1016/j.ijbiomac.2020.02.191",
      "source_type": "primary study report",
      "study_group": "PMID32097740",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Consensus says alginate-chitosan carriers protect normal cells and tissues.",
      "result_comparison": "The original abstract reports release, mucin/flow and H1299 cell activity, then makes a broad protection conclusion. Our original-body access is unavailable, so an independent normal-tissue endpoint was not verified. Its abstract supports a delivery lead, not clinical proof of protection.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/32097740/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\examinations\\original-65-67-6000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "30027204",
      "doi": "10.1001/jamaoncol.2018.2487",
      "source_type": "primary study report",
      "study_group": "PMID30027204",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Consensus separates alternative/complementary-care survival cohorts from laetrile-specific efficacy.",
      "result_comparison": "Original abstract agrees that refusal is important: mortality association becomes nonsignificant after refusal/delay adjustment. This observational attenuation is not randomized mediation proof, not a compound-specific hazard ratio and not evidence that every complementary use causes death.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/30027204/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\examinations\\original-45-65-3600.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "22734852",
      "doi": "10.1186/1477-7819-10-118",
      "source_type": "primary study report",
      "study_group": "PMID22734852",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Provider uses refusal cohorts as separate evidence about treatment substitution.",
      "result_comparison": "OriginalMethods confirms retrospective primary-treatment refusal, limited age/year/stage matching and exclusion of older patients. The association is clinically relevant but cannot identify laetrile exposure or remove every selection factor.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/22734852/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\examinations\\original-45-65-3600.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\body-presentation-receipts\\22734852-s1-p0-1.json"
      ]
    }
  ],
  "grade_changed": false,
  "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.",
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_remaining_priority_20_22_2026-10-12\\laetrile-cancer-treatment\\consensus-browser-2026-10-12.json",
      "sha256": "499362c3b58d147054cb575d8239a72da8dc7ca1b0722f34d3cd9ff65e5973fa"
    }
  ],
  "independent_blinded_audit": false,
  "cutoff": "2026-10-12",
  "completed_utc": "2026-10-12T21:01:18.842067+00:00",
  "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them."
}